The present invention relates to an insulin like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia including benign prostatic hyperplasia (BPH) prostate cancer and particularly CRPC wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.
